Mersana Therapeutics
↗Cambridge, USA
Mersana Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel antibody-drug conjugates (ADCs) for the treatment of cancer. The company utilizes its proprietary Dolasynthen and Immunosynthen platforms to design ADCs with optimized efficacy, safety, and tolerability profiles. Its lead assets target high unmet needs in oncology, including triple-negative breast cancer and rare tumors like adenoid cystic carcinoma.
In January 2026, Mersana was acquired by Day One Biopharmaceuticals to bolster Day One's oncology pipeline. Mersana now operates as a wholly-owned subsidiary, focusing on advancing its lead candidate, Emi-Le (emiltatug ledadotin), and maintaining its high-value strategic collaborations with global pharmaceutical leaders.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$25M-$50M
Founded:2001
Ownership:subsidiary
Status:operating
FUNDING
Stage:Acquired
Total Raised:$289M
Investors:Bain Capital Life Sciences, New Enterprise Associates (NEA), Wellington Management, F-Prime Capital
STOCK
Exchange:NASDAQ
Ticker:MRSN (Delisted Jan 2026)
Market Cap:$145M (at time of acquisition)
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1 (Dose Expansion)
Modalities:ADC, mAb, STING Agonist
Active Trials:2
Trial Phases:Phase 1: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Day One Biopharmaceuticals
Acquired By:Day One Biopharmaceuticals (2026-01-01)
Key Partnerships:GSK (XMT-2056 global license), Janssen/J&J (Dolasynthen collaboration), Merck KGaA (Immunosynthen collaboration)
COMPETITION
Position:Niche Player
Competitors:Seagen (Pfizer), Daiichi Sankyo, ImmunoGen (AbbVie), Sutro Biopharma
LEADERSHIP
Key Executives:
Martin Huber - CEO
Brian DeSchuytner - COO & CFO
Scientific Founders:Timothy Lowinger
Board Members:Anna Protopapas, Andrew Hack
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Mersana Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.